Monday, February 04, 2019 11:41:04 AM
Although some attempts have been made at debunking mineral oil, I think all of those attempts have overlooked some important data – the actual studies done on mineral oil’s effect on the absorption of fat soluble vitamins. The studies are quite old – actually in the period just after WWII. What one study found was that mineral oil in higher quantities, consumed with the mineral oil mixed directly into the food, interfered with the absorption of Vitamin A. However at a dose of 2.5 grams per meal (twice a day) – the mineral oil had no effect on Vitamin A levels. Very nice of that study to have gone down to 2.5 grams as the dosage that was used in REDUCE-IT placebo arm was 2 grams twice daily at mealtime. Most statins are taken at bedtime, but a few timed-release statins are taken at the evening meal. As was pointed out by Mr. Lyon in his article for Seeking Alpha is that the small intestine, where nutrients and statins are both absorbed, is about 20 feet long. A small dosage of mineral oil (under 2.5 grams) cannot coat a sufficient surface of the small intestine to significantly interfere with fat-soluble vitamin uptake. This also was the finding, with the mineral mixed directly into the food and therefore getting to the small intestine simultaneously with the food. However, if we assume at least some of the REDUCE-IT participants took their medication as prescribed, the evening dose of mineral oil would precede the statin dose by 2-3 hours – the mineral oil would have passed to the large intestine, by that time. Even if some participants were “lazy” and took the statin with the evening dosage of placebo mineral oil, the dosage of 2 grams would have had a negligible effect on statin absorption. Another factor to consider is the timing of statin and mineral oil to pass from stomach to small intestine. The mineral oil was in capsules and various statins were used in REDUCE-IT. The dissolve rate of all these different pills could not have been exactly the same. So not only do we have a very small dosage of mineral oil, theoretically most of the participants should have consumed it hours before the statin dosage and even if they were taken together, time separation of uptake would have been greater than in studies where the mineral oil was mixed directly into food.
The second thought on mineral oil is one that hopefully Amarin is looking into with the trial data. While most statins are fat soluble (and therefore would likely be affected by mineral oil in large doses – 15-30 grams, sufficient to cover more of the small intestine,) two statins are water soluble and likely would have no interaction with mineral oil. Those statins are pravastatin and rosuvastatin. Of the 4000-plus participants in the placebo arm, some good percentage was likely on pravastatin. By comparing the average changes in LDL C between fat soluble and water soluble statin takers, Amarin ought to be able to further isolate any effects of mineral oil. My guess is that given the low dose of mineral oil, the group differences will be very minimal or non-existent. Such an analysis would be useful for the FDA submission. Amarin obviously has thought along similar lines as they already had looked at the RRR in placebo arm of those whose LDL C had gone down and those who had gone up. Remember that the RRR was actually better for those whose LDL C had gone up – indicating that the minor LDL C changes had no effect on the positive benefit seen by Vascepa arm. Last thought on all the fear being spread about this issue – LDL C in placebo arm went up 7 points – it was so low already that this was a 10% change. It wasn’t as if LDL C changed from 200 to 220, the average went from 77 to 84. The Vascepa side also rose from 74 to 76. What the fear mongerers fail to mention is that these LDL C levels are still in the ideal range. I have seen no convincing study that shows a significant change in CV events when LDC ranges from 76 to 84. One recent study actually had patients with LDL C in low 80s fare better than those with LDL C lowered to low 70s.
Posted to yahoo as well --- thoughts?
Recent AMRN News
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
FEATURED North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • Jul 18, 2024 9:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM